TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04954690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Program of exercise for Recipients of Kidney Transplantation (WC)
Description: Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)
Description: Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT05460962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing excercises
Description: Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
Study: NCT05939648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Bivalent mRNA Vaccine
Description: 100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
Study: NCT05936892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity aerobic training
Description: upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity resistance training
Description: upper extremity resistance training Overall session time will be 40-45 minutes
Study: NCT05818306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-001
Description: Live biological product BL-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-001
Description: Live biological product BL-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-001
Description: Live biological product BL-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-001
Description: Live biological product BL-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05853224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine
Description: The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine
Description: The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs
Study: NCT06088108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cornell treadmill exercise protocol
Description: Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
Study: NCT05553431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
Study: NCT05295472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grapholearn
Description: GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
Study: NCT06557382

Intervention type: BEHAVIORAL
Intervention: Cognitive tests and reading-related evaluations
Description: Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
Study: NCT05295472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vector
Description: A computer game focusing on children's development of mathematic skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual schooling
Description: No GL or Math computer games, only the usual schooling
Study: NCT04746248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient labor induction
Description: The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient labor induction
Description: The participants are induced following standard inpatient care
Study: NCT05049616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE Inhibitors and Diuretics
Description: Hctz/Lisinopril (brand name: Zestoretic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: Extended release nifedipine
Study: NCT06556134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Iron Sucrose
Description: Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
Study: NCT05388487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 45 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT06534684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
Study: NCT05388487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 90 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 120 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 160 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 120 mg or 180 mg
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT05007704

Intervention type: BEHAVIORAL
Intervention: Global Experts Consensus opinion using Delphi Methodology
Description: The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
Study: NCT05195840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Treatment for Eating Disorders
Description: The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Eating Disorders
Description: The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
Study: NCT06036823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin regular
Description: Intravenous insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin regular
Description: Intravenous insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 50
Description: to be given to both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 50
Description: to be given to both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: to be given to all patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: to be given to all patients
Study: NCT05070195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam Maleate, tablet, oral
Study: NCT05348421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FTPB
Description: A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block
Description: A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
Study: NCT05901558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies for Toddler ASD with Remote-therapy (STAR)
Description: The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community intervention
Description: Regular community intervention
Study: NCT05130060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer Peptide Vaccine PolyPEPI1018
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT06555523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection
Description: The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded injection
Description: The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
Study: NCT05880732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline isotonic solution
Description: only 250 ml of normal saline isotonic solution 30 minutes before induction,
Study: NCT05190666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE Weight Loss program
Description: 12 month phone-based behavioral weight loss program

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Chronic Disease Self-Management
Description: 12 month phone-based chronic disease self-management program
Study: NCT05810480

Intervention type: DIAGNOSTIC_TEST
Intervention: polyreactive immunoglobulin G
Description: Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: polyreactive immunoglobulin G
Description: Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
Study: NCT06556303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure
Study: NCT06313138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Individual and Family Enhancement Program
Description: The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.

Intervention type: OTHER
Group type: OTHER
Intervention: The Individual and Family Enhancement Program
Description: The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
Study: NCT06333561

Intervention type: PROCEDURE
Intervention: Hepatic arterial infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.

Intervention type: DRUG
Intervention: Lenvatinib
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Study: NCT05481333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol
Study: NCT06333561

Intervention type: DRUG
Intervention: Lenvatinib
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day

Intervention type: DRUG
Intervention: Tislelizumab
Description: 200mg intravenously every 3 weeks
Study: NCT05481333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol
Study: NCT06333561

Intervention type: DRUG
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks

Intervention type: DRUG
Intervention: Sintilimab
Description: 200mg intravenously every 3 weeks

Intervention type: DRUG
Intervention: Camrelizumab
Description: 200mg intravenously every 3 weeks
Study: NCT05460962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing excercises
Description: Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises +and progressive muscle relaxation techniques
Description: Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises +and progressive muscle relaxation techniques
Description: Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
Study: NCT05509959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women SHINE
Description: Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Single group session and access to website
Study: NCT04625673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsciPulse
Description: OsciPulse device and standard IPC device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsciPulse
Description: OsciPulse device and standard IPC device
Study: NCT05484141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with blood blow restriction
Description: The rehabilitation program will be applied 2 days a week, for total of 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without blood flow restriction
Description: The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
Study: NCT05103449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Coaching
Description: Video-based coaching sessions after salpingectomy 1 and 2
Study: NCT02483936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40mg + chlorthalidone 12,5mg
Description: 1 tablet a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40mg + chlorthalidone 25mg
Description: 1 tablet a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan 40mg + Hydrochlorothiazide 12,5mg
Description: 1 tablet a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan 40mg + Hydrochlorothiazide 25mg
Description: 1 tablet a day
Study: NCT06532409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA
Description: Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ceftriaxone
Description: Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
Study: NCT05520112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
Description: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
Study: NCT06557707

Intervention type: OTHER
Intervention: Childhood stress
Description: Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.

Intervention type: OTHER
Intervention: Childhood stress
Description: Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
Study: NCT04153942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Any movement out of bed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Any movement out of bed
Study: NCT04664192

Intervention type: OTHER
Intervention: Patient Biospecimen Registry (observational and blood sampling)
Description: Clinical data collected at every blood sample collection visit.